The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients.
Jacques De Greve
No relevant relationships to disclose
Teresa Moran
No relevant relationships to disclose
Marie-Pascale Graas
No relevant relationships to disclose
Daniella Galdermans
No relevant relationships to disclose
Peter Vuylsteke
Other Remuneration - Boehringer Ingelheim
Jean-Luc Canon
No relevant relationships to disclose
Vikram K. Chand
Employment or Leadership Position - Boehringer Ingelheim
Yali Fu
Employment or Leadership Position - Boehringer Ingelheim
Dan Massey
Employment or Leadership Position - Boehringer Ingelheim
Johan Vansteenkiste
No relevant relationships to disclose